Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis [2] CPT Pharmacometrics Syst Pharmacol. 2022 Sep;11(9):1244-1255 Moein A, Lu T, Jönsson S, Ribbing J, Kassir N, Zhang W, Sperinde G, Zhang R, Tang M, Oh YS, Bruno R. GIInflammationJournalPharmacometrics Pharmetheus Affiliates Senior Director, R&D Scientist Siv Jönsson See bio Principal Director, MIDD Consultant & Senior Expert Jakob Ribbing See bio
